Verastem, Inc. Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the closing of a $63.8 million underwritten public offering of 4,255,000 shares of common stock, including 555,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of $15.00 per share to the public. The net proceeds to Verastem from this offering were approximately $59.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Verastem.
Help employers find you! Check out all the jobs and post your resume.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the closing of a $63.8 million underwritten public offering of 4,255,000 shares of common stock, including 555,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of $15.00 per share to the public. The net proceeds to Verastem from this offering were approximately $59.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Verastem.
Help employers find you! Check out all the jobs and post your resume.